Department of Chemistry

Xavier University of Louisiana

Jiawang Liu, Ph.D.
Research Scientist, RCMI Cancer Research Center

Telephone Number: 504-520-7842
Room Number: NCF Annex - Room 372
Email Address:
Short Professional Biography

Research Scientist,
Department of Chemistry
Xavier University of Louisiana, New Orleans, LA 70125

Senior Research Associate
Department of Chemistry
Xavier University of Louisiana, New Orleans, LA 70125

Research Associate
Department of Chemistry
Xavier University of Louisiana, New Orleans, LA 70125

Ph.D., Medicinal Chemistry,
Division of Medicinal Chemistry,
College of Pharmaceutical Sciences, 
Peking University, Beijing 100083, P R China.

B.S., College of Pharmaceutical Sciences.
Peking University, Beijing 100083, P R China.

Research Interest
  1. Estrogen receptor related anticancer drugs.
  2. Potential cytochrome P450 inhibitors.
Current Grant Support

Proposal Title: Multi-Target, Mechanism-Based Drug Design for the Treatment of Breast Cancer: Synthesis, Screening, and Mechanism Investigation of a Ceramide Analog Library
Source of Support: NIH AREA
Period Covered: March 1, 2011- Feb. 29, 2014

Recent Publications

1.         Liu, J.; Pham, P. T.; Skripnikova, E. V.; Zheng, S.; Lovings, L. J.; Wang, Y.; Goyal, N.; Bellow, S. M.; Mensah, L. M.; Chatters, A. J.; Bratton, M. R.; Wiese, T. E.; Zhao, M.; Wang, G.; Foroozesh, M., A Ligand-Based Drug Design, Discovery of 4-Trifluoromethyl-7,8-Pyranocoumarin as a Selective Inhibitor of Human Cytochrome P450 1A2. J Med Chem 2015, 58 (16), 6481-93.


2.         Shimada, T.; Takenaka, S.; Murayama, N.; Kramlinger, V. M.; Kim, J. H.; Kim, D.; Liu, J.; Foroozesh, M. K.; Yamazaki, H.; Guengerich, F. P.; Komori, M., Oxidation of pyrene, 1-hydroxypyrene, 1-nitropyrene and 1-acetylpyrene by human cytochrome P450 2A13. Xenobiotica 2015, Accepted, PMID: 26247835.


3.         Wang, Y.; Tang, J.; Zhu, H.; Jiang, X.; Liu, J.; Xu, W.; Ma, H.; Feng, Q.; Wu, J.; Zhao, M.; Peng, S., Aqueous extract of Rabdosia rubescens leaves: forming nanoparticles, targeting P-selectin, and inhibiting thrombosis. Int J Nanomedicine 2015, Accepted, PMID: 26604756.


4.         Schroeder, R. L.; Tram, P.; Liu, J.; Foroozesh, M.; Sridhar, J., Novel functionalized 5-(phenoxymethyl)-1,3-dioxane analogs exhibiting cytochrome P450 inhibition: a patent evaluation WO2015048311 (A1). Expert Opin Ther Pat 2015, Accepted, PMID: 26514241.


5.         Goyal, N.; Liu, J.; Lovings, L.; Dupart, P.; Taylor, S.; Bellow, S.; Mensah, L.; McClain, E.; Dotson, B.; Sridhar, J.; Zhang, X.; Zhao, M.; Foroozesh, M., Ethynylflavones, highly potent and selective inhibitors of cytochrome P450 1A1. Chem Res Toxicol 2014, 27 (8), 1431-39.


6.         Ponnapakam, A. P.; Liu, J.; Bhinge, K. N.; Drew, B. A.; Wang, T. L.; Antoon, J. W.; Nguyen, T. T.; Dupart, P. S.; Wang, Y.; Zhao, M.; Liu, Y. Y.; Foroozesh, M.; Beckman, B. S., 3-Ketone-4,6-diene ceramide analogs exclusively induce apoptosis in chemo-resistant cancer cells. Bioorg Med Chem 2014, 22 (4), 1412-20.


7.         Liu, J.; Taylor, S. F.; Dupart, P. S.; Arnold, C. L.; Sridhar, J.; Jiang, Q.; Wang, Y.; Skripnikova, E. V.; Zhao, M.; Foroozesh, M., Pyranoflavones: A Group of Small-Molecule Probes for Exploring the Active Site Cavities of Cytochrome P450 Enzymes 1A1, 1A2, and 1B1. J Med Chem 2013, 56 (10), 4082-92.


8.         Liu, J.; Sridhar, J.; Foroozesh, M., Cytochrome P450 family 1 inhibitors and structure-activity relationships. Molecules 2013, 18 (12), 14470-95.


9.         Jin, S.; Wang, Y.; Zhu, H.; Zhao, S.; Zhao, M.; Liu, J.; Wu, J.; Gao, W.; Peng, S., Nanosized aspirin-Arg-Gly-Asp-Val: delivery of aspirin to thrombus by the target carrier Arg-Gly-Asp-Val tetrapeptide. ACS Nano 2013, 7 (9), 7664-73.


10.       Liu, J.; Beckman, B. S.; Foroozesh, M., A review of ceramide analogs as potential anticancer agents. Future Med Chem 2013, 5 (12), 1405-21.


11.       Zhang, H.; Gay, S. C.; Shah, M.; Foroozesh, M.; Liu, J.; Osawa, Y.; Zhang, Q.; Stout, C. D.; Halpert, J. R.; Hollenberg, P. F., Potent mechanism-based inactivation of cytochrome P450 2B4 by 9-ethynylphenanthrene: implications for allosteric modulation of cytochrome P450 catalysis. Biochemistry 2013, 52 (2), 355-64.


12.       Liu, J.; Nguyen, T. T.; Dupart, P. S.; Sridhar, J.; Zhang, X.; Zhu, N.; Stevens, C. L.; Foroozesh, M., 7-Ethynylcoumarins: selective inhibitors of human cytochrome P450s 1A1 and 1A2. Chem Res Toxicol 2012, 25 (5), 1047-57.


13.       Sridhar, J.; Liu, J.; Foroozesh, M.; Klein Stevens, C. L., Inhibition of cytochrome p450 enzymes by quinones and anthraquinones. Chem Res Toxicol 2012, 25 (2), 357-65.


14.       Li, L.; Wu, J.; Zhao, M.; Wang, Y.; Zhang, H.; Zhang, X.; Gui, L.; Liu, J.; Mair, N.; Peng, S., Poly-α,β-DL-aspartyl-L-cysteine: a novel nanomaterial having a porous structure, special complexation capability for Pb(II), and selectivity of removing Pb(II). Chem Res Toxicol 2012, 25 (9), 1948-54.


15.       Sridhar, J.; Liu, J.; Foroozesh, M.; Stevens, C. L., Insights on cytochrome p450 enzymes and inhibitors obtained through QSAR studies. Molecules 2012, 17 (8), 9283-305.


16.       Sridhar, J.; Ellis, J.; Dupart, P.; Liu, J.; Stevens, C. L.; Foroozesh, M., Development of Flavone Propargyl Ethers as Potent and Selective Inhibitors of Cytochrome P450 Enzymes 1A1 and 1A2. Drug Metab Lett 2012, 6 (4), 275-84.


17.       Yang, G.; Zhu, H.; Zhao, M.; Wu, J.; Wang, Y.; Zheng, M.; Chen, M.; Liu, J.; Peng, S., The application of tetrahydroisoquinoline-3-carbonyl-TARGD(F)F as an anti-thrombotic agent having dual mechanisms of action. Mol Biosyst 2012, 8 (10), 2672-9.


18.       Wang, Y.; Kang, G.; Liu, J.; Zhao, M.; Wu, J.; Zhang, X.; Li, Y.; Zhong, X.; Yang, Y.; Peng, S., Novel potassium N-[(2S,3R,4R,5R)-2,3,4,5,6-pentahydroxylhex-1-yl]-L-amino acid dichloroplatinates(II) with high anti-tumor activity and low side reaction. Metallomics 2012, 4 (5), 441-7.


19.       Zhang, H.; Wang, Y.; Zhao, M.; Wu, J.; Zhang, X.; Gui, L.; Zheng, M.; Li, L.; Liu, J.; Peng, S., Synthesis and in vivo lead detoxification evaluation of Poly-α,β-dl-aspartyl-l-methionine. Chem Res Toxicol 2012, 25 (2), 471-7.


20.       Liu, J.; Wang, Y.; Yang, Y.; Jiang, X.; Zhao, M.; Wang, W.; Wu, G.; Wu, J.; Zheng, M.; Peng, S., Pyrolo[1,2:4,5]-1,4-dioxopyrazino[1,2:1,6]pyrido[3,4-b]indoles: a group of urokinase inhibitors, their synthesis, and stereochemistry-dependent activity. ChemMedChem 2011, 6 (12), 2312-22.


21.       Mei, S.; Liu, J.; Zhao, M.; Wang, W.; Wang, Y.; Wu, G.; Zheng, M.; Peng, S., From Cerius² based stereoview to mouse and enzyme: the model systems for discovery of novel urokinase inhibitors. Mol Biosyst 2011, 7 (9), 2664-9.


22.       Wang, Y.; Kang, G.; Zhao, M.; Wu, J.; Zhang, X.; Yang, Y.; Liu, J.; Peng, S., A new platinum-complex showing easy preparation, promising anti-tumor activity, and better efficacy and distribution properties than oxaliplatin. Mol Biosyst 2011, 7 (12), 3245-52.


23.       Li, C.; Zhang, X.; Zhao, M.; Wang, Y.; Wu, J.; Liu, J.; Zheng, M.; Peng, S., A class of novel N-(1-methyl-β-carboline-3-carbonyl)-N'-(aminoacid-acyl)-hydrazines: aromatization leaded design, synthesis, in vitro anti-platelet aggregation/in vivo anti-thrombotic evaluation and 3D QSAR analysis. Eur J Med Chem 2011, 46 (11), 5598-608.


24.       Wang, Y.; Jiang, X.; Liu, J.; Zhao, M.; Kang, G.; Wu, J.; Peng, L.; Peng, S., HPLC-MS aided PC12 cell systems: to quantitatively monitor the conversion of nitronyl nitroxide in biological systems with and without NO. Mol Biosyst 2011, 7 (5), 1678-83.


25.       Wang, H.; Peng, L.; Zhao, M.; Liu, J.; Zhang, X.; Wang, Y.; Wu, J.; Li, L.; Peng, S., 2-Substituted (S)-2-(3,3-dimethyl-1-oxo-10,10a-dihydroimidazo[1,5-b]isoquinolin-2(1H,3H,5H)-yl)acetic acids: Conformational prediction, synthesis, anti-thrombotic and vasodilative evaluation. Bioorg Med Chem 2011, 19 (2), 871-82.


26.       Wang, W.; Zhao, M.; Wang, Y.; Liu, J.; Wu, J.; Kang, G.; Peng, S., {2-[1-(3-Methoxycarbonylmethyl-1H-indol-2-yl)-1-methyl-ethyl]-1H-indol-3-yl}-acetic acid methyl ester (MIAM): its anti-cancer efficacy and intercalation mechanism identified via multi-model systems. Mol Biosyst 2011, 7 (3), 766-72.


27.       Liu, J.; Jiang, X.; Zhao, M.; Zhang, X.; Zheng, M.; Peng, L.; Peng, S., A class of 3S-2-aminoacyltetrahydro-beta-carboline-3-carboxylic acids: their facile synthesis, inhibition for platelet activation, and high in vivo anti-thrombotic potency. J Med Chem 2010, 53 (8), 3106-16.


28.       Liu, J.; Antoon, J. W.; Ponnapakkam, A.; Beckman, B. S.; Foroozesh, M., Novel anti-viability ceramide analogs: design, synthesis, and structure-activity relationship studies of substituted (S)-2-(benzylideneamino)-3-hydroxy-N-tetradecylpropanamides. Bioorg Med Chem 2010, 18 (14), 5316-22.


29.       Liu, J.; Zhao, M.; Qian, K.; Zhang, X.; Lee, K. H.; Wu, J.; Liu, Y. N.; Peng, S., Benzyl 1,2,3,5,11,11a-hexahydro-3,3-dimethyl-1-oxo-6H-imidazo[3',4':1,2]pyridin[3,4-b]indole-2-substituted acetates: One-pot-preparation, anti-tumor activity, docking toward DNA and 3D QSAR analysis. Bioorg Med Chem 2010, 18 (5), 1910-7.


30.       Sridhar, J.; Jin, P.; Liu, J.; Foroozesh, M.; Stevens, C. L., In silico studies of polyaromatic hydrocarbon inhibitors of cytochrome P450 enzymes 1A1, 1A2, 2A6, and 2B1. Chem Res Toxicol 2010, 23 (3), 600-7.


31.       Zhao, M.; Wang, Y.; Huo, C.; Liu, J.; Li, C.; Zhang, X.; Peng, L.; Peng, S., Lead detoxification activity and ADMET hepatotoxicity of N-(alpha-L-arabino-furanos-1-yl)-L-cysteine. Chem Res Toxicol 2010, 23 (7), 1282-5.


32.       Antoon, J. W.; Liu, J.; Ponnapakkam, A. P.; Gestaut, M. M.; Foroozesh, M.; Beckman, B. S., Novel D: -erythro N-octanoyl sphingosine analogs as chemo- and endocrine-resistant breast cancer therapeutics. Cancer Chemother Pharmacol 2010, 65 (6), 1191-5.


33.       Zhu, N.; Lightsey, D.; Liu, J.; Foroozesh, M.; Morgan, K. M.; Stevens, E. D.; Klein Stevens, C. L., Ethynyl and Propynylpyrene Inhibitors of Cytochrome P450. J Chem Crystallogr 2010, 40 (4), 343-352.


34.       Antoon, J. W.; Liu, J.; Gestaut, M. M.; Burow, M. E.; Beckman, B. S.; Foroozesh, M., Design, synthesis, and biological activity of a family of novel ceramide analogues in chemoresistant breast cancer cells. J Med Chem 2009, 52 (18), 5748-52.


35.       Liu, J.; Zhao, M.; Cui, G.; Zhang, X.; Wang, J.; Peng, S., Methyl (11aS)-1,2,3,5,11,11a-hexahydro-3,3-dimethyl-1-oxo-6H-imidazo-[3',4':1,2]pyridin[3,4-b]indol-2-substituted acetates: synthesis and three-dimensional quantitative structure-activity relationship investigation as a class of novel vasodilators. J Med Chem 2008, 51 (15), 4715-23.


36.       Liu, J.; Wu, G.; Cui, G.; Wang, W. X.; Zhao, M.; Wang, C.; Zhang, Z.; Peng, S., A new class of anti-thrombosis hexahydropyrazino-[1',2':1,6]pyrido-[3,4-b]-indole-1,4-dions: design, synthesis, logK determination, and QSAR analysis. Bioorg Med Chem 2007, 15 (17), 5672-93.


37.       Liu, J.; Cui, G.; Zhao, M.; Cui, C.; Ju, J.; Peng, S., Dual-acting agents that possess reversing resistance and anticancer activities: Design, synthesis, MES-SA/Dx5 cell assay, and SAR of Benzyl 1,2,3,5,11,11a-hexahydro-3,3-dimethyl-1-oxo-6H-imidazo[3',4':1,2]pyridin[3,4-b]indol-2-substitutedacetates. Bioorg Med Chem 2007, 15 (24), 7773-88.

38.       Wu, G.; Liu, J.; Bi, L.; Zhao, M.; Wang, C.; Baudy-Floc'h, M.; Ju, J.; Peng, S., Toward breast cancer resistance protein (BCRP) inhibitors: design, synthesis of a series of new simplified fumitremorgin C analogues. Tetrahedron 2007, 63 (25), 5510-28.

Department of Chemistry